AI Article Synopsis
Article Abstract
Background: The increasing incidence of multidrug-resistant tuberculosis (MDR-TB) infections has created a need for new effective drugs that also target extensively drug-resistant tuberculosis (XDR-TB) and/or augment the activities of existing drugs against tuberculosis.
Aim: This study searched natural products for a new lead compound that targets MDR/XDR-TB.
Methods: An active compound was purified from the roots of Cynanchum atratum Bunge (Asclepiadaceae) after screening 1640 plant extracts, and its inhibitory effects against MDR/XDR strains and synergistic effects with existing anti-TB drugs were assessed using the resazurin, MGIT, and checkboard assays.
Results: (-)-Deoxypergularinine, purified from the roots of C. atratum, inhibited not only M. tuberculosis but also MDR/XDR strains. The minimum inhibitory concentrations (MICs) of (-)-deoxypergularinine for H37Ra, H37Rv, MDR, and XDR strains were all about 12.5 µg/ml. Moreover, combinations of (-)-deoxypergularinine with the first-line standard drugs rifampicin or isoniazid afforded six- and eight-fold reductions in drug MIC values, respectively, against strain H37Ra.
Conclusions: (-)-Deoxypergularinine exerts anti-tubercular activities not only against normal tuberculosis strains but also MDR/XDR strains, and synergic effects with rifampicin and isoniazid for the H37Ra strain. The alkaloid may be valuable for targeting M/XDR M. tuberculosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phymed.2016.02.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tuberculosis (TB) is historically the world's deadliest infectious disease. New TB drugs that can avoid pre-existing resistance are desperately needed. The β-lactams are the oldest and most widely used class of antibiotics to treat bacterial infections but, for a variety of reasons, they were largely ignored until recently as a potential treatment option for TB.
View Article and Find Full Text PDFEpidemiology, antimicrobial resistance profile, associated risk factors and management of carbapenem resistant Klebsiella pneumoniae in children under 5 with suspected sepsis in Ethiopia.
BMC Infect Dis
December 2024
Institute of Biotechnology, Addis Ababa University P.O.Box.1176, Addis Ababa, Ethiopia.
Background: Early detection and treatment of carbapenem-resistant Klebsiella pneumoniae (CRKP) could reduce the risk of developing life-threatening sepsis in childhood. However, little is known about sepsis caused by CRKP in children under-5 in developing countries. This study aimed to determine the epidemiology, antimicrobial resistance profile, associated risk factors and management of CRKP in children under-5 with sepsis in Ethiopia.
View Article and Find Full Text PDFCefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection.
Infect Drug Resist
November 2024
Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland.
Background: MDR/XDR constitutes a difficult to treat bacteria in a number of infections as there are few therapeutic options. Promising drugs in such cases can be cefiderocol, aztreonam and ceftazidime/avibactam or meropenem/vaborbactam.
Case Presentation: A 72-year-old female patient with sepsis caused by KP NDM, OXA 48 was admitted to the Intensive Care Unit, immediately after an emergency graftectomy (of a recently transplanted kidney) complicated with bleeding.
Genetic Characterization of Multidrug-Resistant and Synergy Assessment of Antimicrobial Combinations.
Antibiotics (Basel)
November 2024
Department of Infectious Diseases, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.
Article Synopsis
- The study investigates the effectiveness of various antimicrobial combinations against multidrug-resistant (MDR) and extensive drug-resistant (XDR) strains of a prominent nosocomial pathogen that poses a significant public health threat.
- Researchers assessed the genetic characteristics of 100 isolates, noting high prevalence of drug resistance genes and variations in expression of efflux pumps and porins, indicating complex resistance mechanisms.
- Two promising combinations, levofloxacin-ampicillin/sulbactam and meropenem-colistin, showed synergistic effects in inhibiting bacterial growth, but differing results across testing methods suggest further research is required to optimize treatment strategies.
The Prevalence of Multidrug-Resistant and Extensively Drug-Resistant Infections in Respiratory Intensive Care Unit, Causative Microorganisms and Mortality.
Infect Drug Resist
November 2024
Infectious Diseases and Clinical Microbiology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Aim: This study aims to analyze the incidence of multidrug-resistant (MDR) retrospectively and extensively drug-resistant (XDR) infections, characteristics of patients with these infections, causative microorganisms, and mortality rates in a tertiary respiratory intensive care unit (ICU).
Material And Method: Between 01.01.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!